News Hub | News Direct

The Growing Opportunity in Agricultural Drones: Four Stocks to Watch in Precision Ag

ZENA

The agriculture drone market is exploding. Valued at 6.1 billion dollars in 2024, it is expected to nearly quadruple to 23.8 billion dollars by 2032, growing at a compound annual rate of 18.5 percent. This rapid expansion is driven by rising demand for precision farming tools that improve efficiency, reduce chemical use, and increase crop yields. Advances in drone technology, AI, and supportive regulations are making drone-powered crop monitoring, spraying, and data analysis practical and cost-effective for farms of all sizes. With such strong growth underway, it makes sense to pay attention to companies leading the charge in agricultural drones. Let’s look at four stocks worth watching in this fast-moving sector. ZenaTech, Inc. (Nasdaq: ZENA) is positioning itself as a leading force in the precision agriculture drone market by combining autonomous drone hardware with advanced AI software and a scalable Drone as a Service business model. Its wholly owned subsidiary, ZenaDrone, designs and manufactures multifunction drones used across agriculture, defense, logistics, and inspection sectors. ZenaTech’s flagship agricultural drone, the ZenaDrone 1000, is a medium-sized vertical takeoff and landing (VTOL) quadcopter capable of lifting up to 40 kilograms. The platform recently received FAA Part 137 approval, allowing the company to commercially conduct crop spraying operations—including pesticides, herbicides, fungicides, fertilizers, and seed distribution—across the United States. This regulatory milestone unlocks significant domestic revenue potential while paving the way for expansion into Europe. CEO Shaun Passley, Ph.D., commented, “FAA Part 137 approval now enables our team to finish final testing and commence sales of our agriculture solutions. Drones offer a more precise, efficient, cost-effective, and safer alternative to traditional methods.” ZenaTech’s Drone as a Service (DaaS) model offers flexible subscription and pay-per-use options, giving farmers access to drone technology without the upfront investment, pilot certification, or regulatory burden. In May 2025, the company opened a European headquarters in Dublin, Ireland, to support its agricultural drone operations in a market projected to grow at 28.6 percent annually and reach $43.2 billion by 2032, according to Market Data Forecast. Passley added, “The expansion of our Dublin office marks a new chapter in our strategy to scale our drones and DaaS offerings globally while servicing the fastest-growing agricultural drone markets located in Europe.” Beyond agriculture, ZenaTech has acquired six U.S. companies to strengthen its drone-enabled services in land surveying and powerline inspection. These moves create operational synergies across verticals and accelerate adoption of its autonomous platforms. With the global agriculture drone market expected to grow from $6.1 billion in 2024 to $23.78 billion by 2032, ZenaTech is well positioned to capitalize through its FAA-certified hardware, expanding DaaS footprint, and international rollout. AgEagle Aerial Systems (NYSE: UAVS) has been a precision agriculture and unmanned aerial systems (UAS) pioneer since its founding in 2010. The company designs and delivers professional-grade fixed-wing drones, sensors, and software solutions serving customers in agriculture, energy, construction, and government. In Q1 2025, UAVS reported net income of $7.06 million, reversing a $6.32 million loss from the prior year. Gross margin improved to 58.5 percent from 50.2 percent, while operating expenses fell nearly 28 percent—reflecting stronger execution, increased drone sales, and financial discipline. The company has remained active on the regulatory front, participating in FAA discussions around Rule Part 108, which could enable broader Beyond Visual Line of Sight (BVLOS) operations. CEO Bill Irby emphasized that this regulatory evolution will unlock more commercial drone use across agriculture and other industries. Technologically, UAVS partnered with Ascent AeroSystems to integrate the RedEdge-P multispectral camera into the rugged Spirit UAV platform—enhancing precision and efficiency for farm applications. It also teamed up with India-based Vyom Drones to license manufacturing and expand into one of the world’s fastest-growing agricultural drone markets. With a return to profitability, regulatory momentum, and new strategic partnerships, AgEagle is well positioned to ride the accelerating growth of drone-enabled agriculture. Investors looking for scale in precision agriculture might also consider CNH Industrial (NYSE: CNH), a global machinery leader integrating automation across tractors, sprayers, and harvesters. Through brands like Case IH and New Holland, CNH is deploying AI-driven spraying systems and sensor-laden harvesters to optimize crop inputs and yields. While Q1 results reflected soft demand—with revenue down 21 percent and ag EBIT off 64 percent—the company’s ongoing tech innovation and global footprint suggest potential upside once the cycle turns. Meanwhile, AeroVironment (NASDAQ: AVAV) provides exposure to drone systems from a national security angle. With $820.6 million in 2025 revenue and $1.2 billion in bookings, AVAV maintains a strong backlog. However, its agricultural exposure is minimal, and its recent $750 million equity raise may weigh on short-term performance. As agricultural innovation accelerates, the market is shifting toward platforms that combine autonomy, analytics, and accessibility. While industrial giants and defense players bring scale, focused firms like ZenaTech and AgEagle are delivering end-to-end precision agriculture solutions purpose-built for this moment. For investors seeking exposure to one of the fastest-growing applications of drone technology, these names offer compelling, targeted entry points. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by the company to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 Mark@razorpitch.com Company Website http://razorpitch.com

July 02, 2025 07:00 AM Eastern Daylight Time

Investing in Innovation: Four Small-Caps Driving the Future of Pain Therapy

NTRB

The global transdermal patch market is quietly gaining ground. Valued at $7.8 billion in 2023, it is projected to reach nearly $10.95 billion by 2030. Within that, pain patches are leading the way, expected to grow from $4.8 billion in 2021 to $7.3 billion by 2031. But this growth is not just about convenience. Transdermal drug delivery is solving critical problems, from managing chronic pain in aging populations to delivering medications without needles. Most importantly, it offers a safer alternative to traditional opioid use. The abuse-deterrent opioid segment, while still relatively small, is gaining momentum. It is projected to more than double between 2024 and 2030, driven by regulatory pressure, clinical demand, and advances in technology. That convergence is starting to attract serious investor interest. This creates a promising setup for small-cap biopharma companies focused on innovative pain and rescue therapies. Several are moving closer to meaningful catalysts such as New Drug Application submissions and early-stage commercial progress. Here are a few stocks positioned to benefit from this overlooked but vital shift in drug delivery. Nutriband Inc. (NASDAQ: NTRB) is positioning itself as a disruptive force in the opioid pain management space with its lead product candidate, AVERSA Fentanyl, a transdermal patch designed to deter abuse, misuse, and accidental exposure. At the core of this innovation is Nutriband’s proprietary AVERSA technology, which leverages an aversive agent coating to address the most common form of fentanyl patch abuse—oral consumption. According to a 2022 market analysis by Health Advances, AVERSA Fentanyl has the potential to reach peak annual US sales of between 80 million and 200 million dollars. Unlike many early-stage biotechs, Nutriband is generating revenue today. Through its Pocono Pharma subsidiary, which produces kinesiology tape now sold in retail giants like Walmart, Walgreens, Target, and CVS, the company recorded 667 thousand dollars in revenue in the first quarter of 2025, a 63 percent year-over-year increase. This revenue stream helps fund development and reduces dilution risk, a key differentiator in a capital-intensive sector. Development of AVERSA Fentanyl continues to progress. Nutriband recently completed the commercial manufacturing process scale-up with its partner Kindeva Drug Delivery, a global CDMO that produces millions of transdermal patches annually. Together, they are preparing to file an Investigational New Drug application with the FDA, a crucial step ahead of the planned human abuse liability clinical study. The company is pursuing the 505(b)(2) pathway, which may allow for a faster and more efficient route to market. Regulatory momentum is supported by growing recognition of the public health risks tied to transdermal opioid misuse. AVERSA Fentanyl is aligned with the FDA’s Opioids Action Plan and has been engineered to make fentanyl patches safer without restricting access for legitimate patients. The product may also benefit from regulatory pressure to shift all fentanyl patch formulations toward abuse-deterrent formats, similar to previous changes required for oxycontin generics. Nutriband’s AVERSA platform is protected by a broad international IP portfolio with patents issued in 46 countries. Most recently, the company was granted a US patent for its transdermal abuse-deterrent system in June 2025, further strengthening its competitive moat. Nutriband’s inclusion in the Russell Microcap, Russell Microcap Growth, Russell 3000E, and Russell 3000E Growth indexes signals growing institutional awareness. Management believes this milestone reflects accelerating progress toward building shareholder value and positioning AVERSA Fentanyl as a potential category leader in opioid safety. With real revenue, a large addressable market, strong IP, and a progressing regulatory timeline, Nutriband Inc. offers investors early exposure to a unique solution in the fight against opioid abuse. Collegium Pharmaceutical, Inc. (Nasdaq: COLL) is quietly becoming a standout in the pain and neuropsychiatry treatment markets, driven by consistent revenue growth, expanding product reach, and shareholder-focused capital allocation. In the first quarter of 2025, Collegium reported net revenue of 177.8 million dollars, up 23 percent year-over-year, with its ADHD medication Jornay PM growing prescriptions by 24 percent and generating 28.5 million dollars in revenue for the quarter. The company has now completed a major field force expansion, bringing its ADHD sales team to approximately 180 representatives to support continued growth in this space. The company’s core pain portfolio also continues to deliver. In Q1 2025, Collegium generated 149.2 million dollars in revenue from its chronic pain medications, with each of its flagship products—Belbuca, Xtampza ER, and the Nucynta franchise—posting year-over-year growth. Belbuca alone brought in 51.7 million dollars, up 2 percent, while Xtampza ER and Nucynta added 47.6 million and 47.1 million, respectively. Collegium’s strong financial performance has supported aggressive yet balanced capital deployment. In May, the company announced a 25 million dollar accelerated share repurchase, part of a broader 150 million dollar program, reflecting confidence in its long-term value. The company ended Q1 with 197.8 million dollars in cash, up from 162.8 million at year-end 2024, and generated over 55 million dollars in cash from operations. With reaffirmed full-year guidance, expanding leadership, and strong product execution, Collegium is establishing itself as a consistent revenue generator in the biopharma space. Its dual focus on responsibly managed pain treatments and a fast-growing ADHD franchise gives it a diversified growth engine in two high-need therapeutic areas. For investors seeking a profitable, commercial-stage biotech with upside potential and disciplined management, Collegium deserves a closer look. Assertio Holdings, Inc. (Nasdaq: ASRT) is a specialty pharmaceutical company in transition, executing a focused strategy to strengthen its commercial platform while shedding legacy risks. In the first quarter of 2025, the company reported 26 million dollars in total net product sales, tracking in line with its full-year guidance. Management emphasized that sales from its growth assets, particularly Rolvedon and Sympazan, are outperforming internal expectations, providing a strong foundation for Assertio’s near-term revenue expansion. Assertio is actively streamlining operations and reducing legal exposure, having settled multiple longstanding lawsuits, including the DOJ False Claims Act case and opioid-related liabilities. A major structural move was the divestiture of Assertio Therapeutics, which held legacy legal obligations and low-value assets. That transaction has now fully removed Assertio Holdings and its current subsidiaries from all opioid litigation. This cleanup effort allows management to focus entirely on high-potential assets and business development. Rolvedon, a treatment for chemotherapy-induced neutropenia, continues to show momentum, with Q1 sales outperforming despite prior-quarter inventory stocking. Management expects steady growth for the product throughout 2025. Sympazan, a prescription oral film for Lennox-Gastaut syndrome, also benefited from a revised promotional strategy, driving a 6.5 percent year-over-year increase in prescriptions during the quarter. With a cleaned-up balance sheet, narrowed commercial focus, and a disciplined approach to portfolio expansion, Assertio is entering a new phase. The company aims to become a preferred partner in specialty pharma, leveraging its commercial infrastructure to onboard new products across therapeutic areas. For investors seeking a turnaround story with defined growth levers and reduced legal overhang, Assertio may be one to watch in 2025. Aquestive Therapeutics, Inc. (Nasdaq: AQST) is a pharmaceutical company focused on advancing medicines that improve patients’ lives through innovative science and delivery technologies. The company develops orally administered products to deliver complex molecules, offering novel alternatives to invasive standard therapies. Aquestive currently has four licensed commercial products marketed globally and serves as the exclusive manufacturer for these products. It also collaborates with pharmaceutical partners using proprietary technologies like PharmFilm and has established drug development and commercialization capabilities. The company is progressing a late-stage proprietary candidate, Anaphylm™, an oral sublingual film for severe allergic reactions including anaphylaxis, alongside an early-stage epinephrine prodrug topical gel, AQST-108, targeting dermatological conditions such as alopecia areata. In Q1 2025, Aquestive submitted its NDA for Anaphylm and is preparing for a potential U.S. launch in early 2026, pending FDA approval. The NDA includes comprehensive adult and pediatric clinical data demonstrating a pharmacokinetic profile consistent with existing epinephrine autoinjectors. Aquestive has expanded its market access and medical affairs teams and is advancing commercial readiness, including plans for regulatory submissions in key international markets. The FDA assigned a PDUFA target action date of January 31, 2026, and may convene an Advisory Committee meeting during the review process. Sales of royalty-based products such as Sympazan® and Azstarys® contributed to revenue during the quarter, while manufacturing revenue declined due to lower Suboxone® volumes but was partially offset by growth in other collaborations. Total revenue for Q1 2025 was $8.7 million, down 28% from $12.1 million in Q1 2024. Research and development expenses decreased slightly, while selling, general, and administrative expenses rose primarily due to regulatory and commercial investments linked to Anaphylm’s launch preparations. Aquestive reported a net loss of $22.9 million for the quarter and held $68.7 million in cash at March 31, 2025. The company has paused sales and marketing activities for Libervant® following a court decision affecting its approval status, with plans to resume patient access in 2027 or sooner if permitted. Aquestive revised its 2025 revenue guidance to $44 to $50 million and non-GAAP adjusted EBITDA loss guidance to $47 to $51 million, reflecting the impact of this change. With its innovative, non-invasive epinephrine treatment nearing regulatory approval, broad IP protection, and a clear commercial strategy, Aquestive is positioned to offer a meaningful new option for patients with severe allergic reactions and to expand its footprint in specialty pharmaceutical delivery. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Awareness Consulting LLC to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

July 02, 2025 06:00 AM Eastern Daylight Time

Financial Gravity Welcomes New Family Office Director Mitch Monson

Financial Gravity Companies, Inc.

Financial Gravity Companies, Inc. (OTC: FGCO) (“Financial Gravity”), welcomes Mitch Monson aboard as a Family Office Director. Mitch is a seasoned financial professional with over 25 years of experience. He truly enjoys working with his clients. His favorite areas of focus are tax-optimized income planning and efficient wealth transfer road mapping for retirees. As a fiduciary, he takes an all-encompassing approach to investing, risk management, legacy planning, and tax planning. Mitch holds a bachelor's degree in Finance from the University of Utah, as well as his Series 65 and life/health licenses. As a Family Office Director, Mitch is responsible for prescribing advanced tax solutions and ensuring his network of partners fill those solutions with fidelity to his plan. He relies on the experts at Financial Gravity, Inc., a true partner -- not just a vendor -- who helps him deliver lower costs, higher tax efficiency, more comprehensive diversification, and more transparent risk management. Mitch shared, “I'm thrilled to join Financial Gravity, a leader in consolidating the typically segregated disciplines of proactive tax planning, wealth management, estate planning, and tax compliance.” Financial Gravity CEO Scott Winters shared, “We are thrilled to have Mitch join us at Financial Gravity. We look forward to a bright future together and continued growth together.” About Financial Gravity Companies, Inc. Our vision at Financial Gravity is to be the industry leader in democratizing family office benefits for the mass affluent American family. Our Turnkey Multi-Family Office Charter revolutionizes financial services by using a multi-disciplinary approach, bringing together all facets of a client’s financial life and empowering them with personalized solutions. The result is an unparalleled client experience. We bring the advantages of the family office model that were once only available to the super-wealthy. We provide coordinated advice, without conflict, regarding taxes, investments, and risk management. This coordination of advice provides both efficiency and tax advantages, which can generate meaningfully higher returns for clients without exposing them to additional portfolio risk. For more information about Financial Gravity Companies, Inc., please visit https://financialgravity.com. Forward-Looking Statements This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert, or change any of them and could cause actual outcomes and results to differ materially from the current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Financial Gravity's business, and Financial Gravity undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Contact Details Scott Winters +1 800-588-3893 scott.winters@financialgravity.com Company Website https://financialgravity.com/

July 02, 2025 06:00 AM Eastern Daylight Time

News Release

Wall Street Analyst Issues Bullish Update on DarioHealth, Reiterates $3 Price Target Highlighting 320% Upside Potential (NASDAQ: DRIO)

Alpha Catalyst

Wall Street analyst Theodore O'Neill of Litchfield Hills Research has reiterated his Buy rating and $3 price target on DarioHealth Corp. (NASDAQ: DRIO)*, highlighting what he sees as significant upside potential of approximately 320% from current trading levels around $0.71. The analyst's updated note comes as recently IPO’d competitor Hinge Health (NYSE: HNGE) currently trades at a $3.53 billion market cap following its successful public debut, creating what O'Neill describes as a stark "valuation gap" with DarioHealth, which has a market capitalization of approximately $31 million despite comparable growth metrics and superior gross margins. GLP-1 Success Validates Platform's Value Proposition The research update particularly emphasized DarioHealth's recent clinical findings presented at the American Diabetes Association's 85th Annual Scientific Sessions. A landmark study of 715 GLP-1 users revealed that patients who discontinued their medication maintained stable outcomes with no significant weight or glucose rebound for at least six months when using Dario's platform. The analyst's report highlights DarioHealth's study findings that demonstrated users who discontinued GLP-1 medication while continuing to use the platform maintained stable outcomes without significant weight or glucose rebound for at least six months. O'Neill points to these clinical results as a key differentiator for the company's value proposition in the expanding GLP-1 market. This clinical validation comes at a critical time as the GLP-1 market for weight loss medications is projected to reach $100 billion by 2030, with employers increasingly struggling to manage the high costs of these drugs while ensuring sustainable patient outcomes. Strategic Partnerships Expand Addressable Market The analyst also highlighted DarioHealth's recent strategic commercial agreement with GreenKey Health announced on June 26, which targets the $150 billion sleep apnea market affecting over 29 million Americans. The collaboration integrates behavioral health, sleep, and cardiometabolic care to deliver a comprehensive solution for employers and health plans seeking to reduce healthcare costs. O'Neill's analysis emphasizes the strategic benefits of DarioHealth's partnership with GreenKey Health, noting how the collaboration combines their respective strengths to create a comprehensive, data-driven solution designed to improve health outcomes, reduce costs, and boost productivity for employers and health plans. Dramatic Valuation Discount Compared to Peers The most compelling aspect of the analyst's thesis is the dramatic valuation contrast between DarioHealth and its peers. Using a discounted future earnings model and comparative peer analysis, O'Neill calculates a fair value of $3 per share. According to the report, If DarioHealth were to trade at this target, its Market Cap/Sales multiple would be approximately 2.2x, which would still be below the peer average of 2.38x, according to the analyst's calculations. This suggests the company remains significantly undervalued even at the target price, especially considering its high growth profile and improving gross margins. The company's B2B2C gross margins now exceed 80%, higher than many competitors, while operating expenses have declined significantly, positioning the company on a path to operational cash flow breakeven by the end of 2025. Financial Outlook Supports Bullish Thesis O'Neill forecasts DarioHealth could reach $35.9 million in revenue for 2025, growing to $66.1 million in 2026, with the company expected to achieve GAAP profitability during 2026. DarioHealth's AI-driven platform serves five chronic conditions through a single interface, diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health, giving it one of the most comprehensive offerings in the industry and positioning it to capitalize on employer and payer trends toward vendor consolidation. As digital health platforms continue to gain traction and the GLP-1 market expands, O'Neill believes DarioHealth remains positioned for potential significant share price appreciation as the market recognizes its comparable business metrics relative to recently validated competitors. ‎ ‎ ‎ This post was originally published on AlphaCatalyst ‎ ‎ Recent News Highlights from Dario Dario and GreenKey Health Announce Strategic Commercial Agreement to Transform Chronic Condition Management and Sleep Health for Payers Nationwide Dario Unveils Groundbreaking GLP-1 and AI-Personalization Digital Health Findings DarioHealth Reports First Quarter 2025 Financial and Operating Results ‎ ‎ ‎ * Paid Advertisement: This content is a paid advertisement. The Author, Wall Street Wire, has received compensation from DarioHealth Corp for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available redditwire.com/terms. We are not responsible for any price targets or market size estimates that may be cited in this article nor do we endorse them, they are quoted based on publicly available news reports and additional price targets may exist that may not have been quoted. Readers are advised to refer to the full reports mentioned on various systems and the disclaimers/disclosures they may be subject to. Contact Details ‎ media.globalmarkets@gmail.com

July 02, 2025 05:46 AM Eastern Daylight Time

News Release

Dr Nazmi Baycin Dubai Emerges as a Global Leader in Aesthetic Medicine Led by Renowned Plastic Surgeon

Rev Up Marketers

Dubai is rapidly solidifying its position as a global capital for aesthetic medicine, with the city’s thriving plastic surgery sector contributing significantly to both healthcare growth and economic diversification. Central to this rise is Dr. Nazmi Baycin, a leading plastic surgeon with over 25 years of experience and a decade of distinguished practice in Dubai. Recent data shows that Dubai conducted over 50,000 aesthetic procedures in 2023, generating an estimated $2.5 billion in market value. With a projected annual growth rate of 7–10%, the emirate is quickly becoming one of the world’s most sought-after destinations for cosmetic and elective medical tourism. Dr. Baycin is recognized for his expertise in procedures such as breast augmentation, female genital surgery, tummy tucks, and chin reshaping. His patient-centered approach, paired with advanced technologies and an artistic eye, has set new benchmarks in aesthetic surgery standards across the region. “Dubai offers an unparalleled combination of clinical excellence, privacy, and cultural accessibility,” said Dr. Baycin. “These qualities continue to attract a growing number of patients, particularly from the Gulf Cooperation Council (GCC) region.” A recent report According to the Dubai Health Authority, more than 691,000 medical tourists visited the emirate in 2023, with nearly half arriving specifically for cosmetic treatments. This influx contributed around AED 1 billion ($280 million) directly to the healthcare sector, and an estimated AED 2.3 billion in indirect revenue across hospitality, real estate, transportation, and wellness services. Dubai’s emergence as a plastic surgery hub is supported by strategic initiatives such as the Dubai Economic Agenda (D33), which aims to double the city’s GDP and enhance its reputation as a global innovation and investment hub. Medical tourism plays a central role in this strategy, with plastic surgery leading the charge. The city’s specialized medical zones—such as Dubai Healthcare City —offer cutting-edge infrastructure, favorable tax conditions, and strong regulatory frameworks, attracting both top-tier talent and international patients. The integration of AI diagnostics, robotic-assisted surgeries, and 3D imaging technology ensures precision, safety, and minimal downtime for patients. Social media has also played a pivotal role in shaping regional aesthetic preferences. Dr. Baycin notes a significant increase in demand for natural-looking, minimally invasive enhancements, particularly among patients from Saudi Arabia, Kuwait, and across the Gulf. “As cultural norms evolve and beauty standards become more globally influenced, personalized aesthetic procedures are gaining popularity,” added Dr. Baycin. “Dubai is meeting that demand with world-class solutions.” With robust government support, advanced medical infrastructure, and a growing influx of high-net-worth individuals seeking discreet care, Dubai is on track to become the global epicenter of aesthetic medicine in the coming decade. About Nazmi Baycin Clinic Nazmi Baycin Clinic is a premier aesthetic surgery practice based in Dubai, led by internationally acclaimed plastic surgeon Dr. Nazmi Baycin. With over 25 years of global surgical experience and more than a decade serving clients in the UAE, the clinic is renowned for delivering advanced, patient-focused cosmetic procedures. Specializing in breast augmentation, female genital surgery, tummy tucks, and facial enhancements, Dr. Baycin combines medical precision with artistic sensibility to provide natural, personalized results. Situated in the heart of Dubai’s medical district, the clinic caters to a diverse international clientele, offering world-class care, discretion, and cutting-edge surgical technologies. For more information, visit www.nazmibaycin.com. Contact Details Nazmi Baycin Dr. Nazmi Baycin info@nazmibaycin.com Company Website https://www.nazmibaycin.com

July 01, 2025 05:30 PM Eastern Daylight Time

News Release

Offshore Accounting Services A Boon for US Businesses says Whiz Consulting

Rev Up Marketers

As U.S. companies grapple with rising operational costs, talent shortages, and increasing compliance demands, offshore accounting services are emerging as a practical and strategic solution. According to Whiz Consulting, an accounting and bookkeeping services provider, offshore accounting has proven to be a game-changer for US businesses seeking efficiency, scalability, and high-quality financial support. “Many organizations today are under immense pressure to manage their financial operations accurately while keeping costs under control,” said a senior executive of Whiz Consulting. “Offshore accounting offers a smart way to achieve both, without compromising on expertise or compliance.” By outsourcing accounting functions to qualified professionals overseas, businesses can tap into a global talent pool at a fraction of the cost of hiring and maintaining a full in-house finance team. Moreover, with time zone advantages and access to the latest cloud-based technologies, offshore teams enable round-the-clock productivity and faster turnaround times, giving businesses real-time insights for better decision-making. Whiz Consulting has been at the forefront of this shift, delivering comprehensive offshore accounting services tailored to meet the unique needs of U.S. businesses. Their services cover the full spectrum of financial functions, including: Bookkeeping Payroll processing (covering form such as form 941, quarterly payroll tax return, form 940 – Annual FUTA) U.S. tax preparation and filing (covering forms such as 1099, 1120, and 1120-S) Accounts payable and receivable management Bank reconciliations Financial reporting Budgeting and forecasting Audit support All services are delivered in strict compliance with U.S. Generally Accepted Accounting Principles (GAAP) and relevant international accounting standards. This ensures clients receive reliable, audit-ready financial data that supports strategic growth and regulatory compliance. What sets apart Whiz Consulting from other accounting and bookkeeping service providers is its dual focus on industry-specific expertise and advanced technology. Their team consists of certified accountants and financial professionals who are well-versed in both the technical and practical aspects of accounting for diverse industries from real estate and ecommerce to healthcare, legal, and other professional services. To further enhance services, Whiz Consulting leverages popular accounting platforms such as QuickBooks, Xero, NetSuite, and Zoho Books. These tools not only enable automation of routine tasks but also strengthen data security, improve accuracy, and allow for seamless integration with clients’ existing systems. Clients benefit from real-time financial visibility, reduced manual workload, and more control over their operations. "Offshore accounting is not just about cost savings it’s about building a smarter, more responsive finance function," the senior executive added. "Our services allows clients to pay only for what they need, scale services up or down based on business cycles, and maintain financial clarity without the overhead of managing a full in-house team." Transparency, ethical standards, and open communication lie at the heart of Whiz Consulting’s approach. The firm takes pride in developing long-term partnerships through consistent performance, proactive support, and measurable outcomes. By aligning closely with each client’s business goals and regulatory requirements, Whiz Consulting has earned a reputation as a trusted offshore partner for companies across the United States. With proven success in streamlining financial operations and delivering tangible business value, Whiz Consulting is ready to lead the wave of offshore accounting excellence. As businesses continue to seek more flexible, scalable, and technology-driven financial solutions, the role of offshore accounting will only grow stronger. About Whiz Consulting Whiz Consulting stands as a strategic partner for businesses globally, specializing in outsourced accounting and bookkeeping services. The company have served the businesses across the US, UK, and Australia streamline their financial operations. With over 10+ years of experience, they delivered tailored solutions that integrate expert knowledge, optimized processes, and advanced technology to ensure scalable, compliant, and insightful financial management. Contact Details Whiz Consulting Dipika Kesariar +1 831-632-9736 info@whizconsulting.net Company Website https://www.whizconsulting.net/

July 01, 2025 05:26 PM Eastern Daylight Time

ALLIES OF SKIN PARTNERS WITH MINDFULNESS EXPERT AND BEST-SELLING AUTHOR CASE KENNY FOR “SKINCARE = SELF-CARE” CAMPAIGN

Allies of Skin

Allies of Skin, the supercharged clinical skincare brand founded by Nicolas Travis, announces its partnership with mindfulness expert and best-selling author Case Kenny to celebrate the connection between skincare and self-care. Renowned for its results-driven routines, personally curated by Nicolas Travis from the brand’s assortment of supercharged clinical skincare, Allies of Skin is taking skincare one step further. Together with Case Kenny, they introduce a powerful perspective: skincare as self-affirmation. Allies of Skin's iconic routines are sealed with a bespoke affirmation created by Case Kenny – restoring the skin while reconnecting you with your sense of self. The collaboration invites consumers to turn their daily regimens into powerful acts of self-connection, blending high-performance formulas with holistic wellness. Affirmations aren’t just an add-on – they're the final, essential step in any skincare routine. Just as an Allies of Skin product seals in skincare benefits, a self-affirmation seals in intention. Great skin has the power to make you feel better – more confident, more centered, and more connected to yourself. Together, Nicolas Travis and Case Kenny are lighting both the inner and outer light for consumers, redefining skincare as a ritual for total well-being. For the collaboration and as an official #ALLIESPartner, Case Kenny will curate bespoke digital affirmation cards which will be available through social “drops,” lead engaging social content centered around mindfulness, skincare, and self-love, host events aimed at building conscious community, and participate in a co-branded influencer seeding to spread the message that skincare equals self-care. FROM THE FOUNDER "It has taken 18 years for me to appreciate the beauty of the scars from my experience with facial necrosis. Through my own healing journey, I discovered Case Kenny and his brilliant work. His words resonate with me on a soul level, and they serve as guiding light on dark days. It is this light that I hope to share with our allies. The unwavering light that comes with being at home in your skin. The light that radiates from within when you are at peace with yourself and your journey. The light that no person or situation can diminish. It’s time for all of us to shine a little brighter," says Nicolas Travis, Founder of Allies of Skin. FROM CASE KENNY "I’m very excited to partner with Allies of Skin because we share the same belief: the light you carry comes from what you’ve healed. I believe the darkness you endure in life only makes your light shine brighter, and Allies of Skin believes the same. They believe that skincare isn’t just about how you look, but how you feel. That how you care for yourself on the outside is a reflection of the self-respect, growth, and peace you’re building within. That your outer glow is a mirror of your inner work. What I love most is their mission to make skincare more human - to honor the ups and downs, to embrace the imperfections, and to remind us that showing up for yourself is enough. That kind of alignment is meaningful," says Case Kenny. To stay updated on drops, events, and inspiration, follow @alliesofskin and @casekenny on Instagram. ABOUT ALLIES OF SKIN Allies of Skin redefines skincare with a “supercharged clinical” approach, maximizing clinically proven actives, protective antioxidants, and supporting the skin barrier. Founded by Nicolas Travis in 2016, the high-performance formulas deliver visible, transformative results in fewer steps, with innovative active ingredients like Epidermal Growth Factors (GF), Copper Tripeptide, and patented Encapsulated Retinaldehyde (Retinal), with the mission of delivering unparalleled skin regeneration and longevity. Contact Details OGAKI Digital Hallie Sawyer +1 818-388-7338 hsawyer@ogakidigital.com Company Website https://us.allies.shop/

July 01, 2025 05:24 PM Eastern Daylight Time

Ontario Bets Big: May Sees Record-Breaking Spending in iGaming Sector

AM Europe

While Ontario's provincial budget for 2025-26, "A Plan to Protect Ontario," outlines a massive $232.5 billion in overall expenditures, a significant and noteworthy portion of the province's economic activity in May was driven by a different kind of spending: record-breaking engagement in its regulated iGaming market. May 2025 marked an unprecedented surge in online gambling within the province, with gross gaming revenue (GGR) from iGaming activities reaching a new monthly record of CA338.0million(approximatelyUS247.0 million). This figure not only surpassed Ontario's previous monthly high of $328.5 million (set in January of this year) by a notable 2.9% but also demonstrated a robust 40.3% increase compared to May of last year and an 8.0% rise from April 2025. This remarkable growth wasn't just in revenue. Total player wagering across all iGaming platforms during May also hit an all-time high, breaking the CA8billion mark for the first time, reaching CA8.07 billion. This represents a 3.5% month-on-month increase and a significant 28.9% year-on-year jump. A Deeper Dive into the Gambling Boom: The data from iGaming Ontario (iGO), the provincial regulator, reveals the driving forces behind this spending spree: Online Casino Dominance: Some of the best online casinos in Canada continued to be the primary engine of the iGaming market, accounting for the lion's share of revenue. In May, online casino activity alone generated CA$259.8 million, a substantial 45.3% increase year-on-year, representing 77% of all iGaming revenue in the province. Player spending on internet casino games also saw a healthy rise, reaching CA$6.96 billion, up 30.9% from the previous year. Strong Sports Betting Performance: Sports betting also contributed significantly, bringing in CA$71.8 million in revenue, a 26.3% increase year-on-year, and holding a 21% market share. Wagering on internet sports betting climbed 18.5% to CA$972.0 million. Steady Online Poker: While a smaller segment, internet poker revenue was up 18.9% to CA$6.3 million, with players spending CA$129.0 million. Active Player Accounts: Despite the revenue and spending records, the number of monthly active player accounts saw a slight dip of 2.0% year-on-year, settling at 1.07 million. However, this was offset by a notable 10.0% increase in average revenue per active player account (ARPPA), which reached CA$316. This suggests that while there may have been a slight reduction in the sheer number of active players, those who were engaged were spending more. As of June 25, Ontario's regulated iGaming market boasts 50 licensed operators running 86 websites, demonstrating a robust and competitive landscape. The success of this regulated environment is evident, with the province's iGaming revenue now significantly outpacing that of other Canadian provinces. This record-setting performance in May underscores the growing consumer appetite for online gambling in Ontario and highlights the effectiveness of the province's regulated market in drawing significant revenue. As the province continues to navigate its broader fiscal landscape, the thriving iGaming sector is clearly a significant and expanding contributor to its economic activity. Contact Details Robert Glenn +1 705-653-7164 Robert@ontariocasinos.ca Company Website https://www.casinolistingonline.com/

July 01, 2025 11:04 AM Eastern Daylight Time

Image

New Digital Insurance research reveals how firms are deploying AI, what they’re getting in ROI and how strategies are evolving

Arizent

Digital Insurance, a leading information resource for executives and innovators in the insurance sector, releases its latest research report, The Cost of AI: The AI Revolution Gathers Steam. Sponsored by Salesforce, the findings reveal adoption of artificial intelligence is rising in the insurance industry, with more than half expecting to implement it within 12 to 18 months — and many already seeing returns. AI is moving from pilot project to enterprise strategy for some organizations, with a growing number of companies already seeing returns on their investments. But as AI deployments scale, so do the price tags — and industry professionals may face tough choices about how to modernize, budget and prioritize. The research offers fresh insight into how industry organizations are implementing AI, what they’re prioritizing and what’s standing in the way of broader success. Based on proprietary research with professionals across the insurance industry, the report reveals how different types of organizations are navigating this next phase of transformation. Key takeaways include: Where companies are finding the most value from their AI investments — and where results are falling short What’s driving organizations to move faster and what’s holding others back How generative AI is reshaping the conversation around customer experience What companies are spending now and how that’s expected to shift in the year ahead “AI investments are already paying off, particularly for firms that have implemented them aggressively to improve efficiency,” says Janet King, SVP, Content Strategy, Research at Arizent, parent company of Digital Insurance. “At this point in the adoption curve, the most advanced companies appear to see more opportunities to reap positive returns, suggesting those at the leading edge could remain in that position for some time.” The data indicates nearly all organizations expect their AI spending to increase to some extent over the next 12 months. Only a few companies expect their spending to remain level or decrease. Organizations that trail their peers will need to accelerate their strategies as much as possible or risk falling further behind as early adopters continue to expand their capabilities. To explore the full findings and see where your organization stands, download the full report: https://www.americanbanker.com/payments/news/embedded-payments-demand-comes-from-health-care-travel About Digital Insurance Digital Insurance is the essential resource for senior executives leading the digital transformation of the insurance industry. Across events and member forums, original research reports and editorial news and analysis, Digital Insurance examines business-critical topics in technology innovation, data advancements, insurtech market trends and transformation strategies. The brand convenes the community around these ideas and insights so they can understand the real-world impact on their firms and the customers they serve. About Arizent Arizent is a business information company that advances professional communities by providing insights and analysis and convening industry leaders. The company uses deep industry expertise and a data-driven platform to deliver its services, which include subscriptions, marketing services, live events and access to Leaders Forum, a digital content platform featuring livestream and on-demand formats. Arizent also connects business communities through leading financial services brands like American Banker, The Bond Buyer, Financial Planning and National Mortgage News, as well as professional services brands like Accounting Today, Employee Benefit News and Digital Insurance. About Salesforce Salesforce is the #1 AI CRM, helping companies connect with customers in a whole new way since 1999. Our product portfolio, Agentforce, brings #1 CRM apps together with trusted AI and data on one integrated platform so companies can grow relationships, productivity, and their bottom line. Salesforce helps insurance firms lower operational costs, grow efficiently, innovate at scale, and personalize customer experiences. With Salesforce, insurance carriers, agencies, and brokerages can connect and empower their entire organization, spanning Marketing, Sales, Service, Data, IT, and Analytics. Our AI-driven, connected platform empowers insurers and their distribution partners to manage all core operations from one system — including product development, quoting, claims, and more. Contact Details Arizent Janet King +1 207-807-4806 janet.king@arizent.com Company Website https://www.arizent.com/

July 01, 2025 11:00 AM Eastern Daylight Time

All Industries

The Growing Opportunity in Agricultural Drones: Four Stocks to Watch in Precision Ag

Investing in Innovation: Four Small-Caps Driving the Future of Pain Therapy

Financial Gravity Welcomes New Family Office Director Mitch Monson

Wall Street Analyst Issues Bullish Update on DarioHealth, Reiterates $3 Price Target Highlighting 320% Upside Potential (NASDAQ: DRIO)

Dr Nazmi Baycin Dubai Emerges as a Global Leader in Aesthetic Medicine Led by Renowned Plastic Surgeon

Offshore Accounting Services A Boon for US Businesses says Whiz Consulting

ALLIES OF SKIN PARTNERS WITH MINDFULNESS EXPERT AND BEST-SELLING AUTHOR CASE KENNY FOR “SKINCARE = SELF-CARE” CAMPAIGN

Ontario Bets Big: May Sees Record-Breaking Spending in iGaming Sector

New Digital Insurance research reveals how firms are deploying AI, what they’re getting in ROI and how strategies are evolving